Amicus Therapeutics, Inc. (FOLD) Advances Chaperone-Enzyme Replacement Therapy (ERT) Combination Platform in Pompe Disease  
2/14/2013 11:12:55 AM

CRANBURY, N.J., and ORLANDO, Fla., Feb. 14, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced positive results from clinical and preclinical studies of the pharmacological chaperone AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease at the Lysosomal Disease Network WORLD Symposium (LDN WORLD).